皮肤恶性黑色素瘤(CMM)是一种具有高度侵袭性的皮肤恶性肿瘤,早期即可发生淋巴或血行转移,致死率高。早期明确诊断及规范化手术治疗是改善预后的关键。而随着近年来分子靶向治疗和免疫治疗的快速发展,晚期CMM尤其是局部不可切除或转移性患者的治疗效果得到明显改善,但未来仍需不断探索。文章就CMM治疗现状进行综述,以期为临床实践提供参考。Cutaneous malignant melanoma (CMM) is a highly aggressive skin malignancy that can metastasize via the lymphatic or hematogenous routes at an early stage, resulting in a high mortality rate. Early accurate diagnosis and standardized surgical treatment are critical to improving prognosis. With the rapid advancements in molecular targeted therapy and immunotherapy in recent years, the treatment outcomes for advanced CMM, particularly in patients with unresectable or metastatic disease, have significantly improved. However, further exploration is needed in the future. This article reviews the current status of CMM treatment to provide a reference for clinical practice.
目的探讨转录因子特异性蛋白1(specificity protein 1,SP1)在NF-κB相关性长链非编码RNA(NF-κB interacting long non-coding RNA,NKILA)影响增生性瘢痕成纤维细胞凋亡中的作用。方法提取并培养增生性瘢痕组织及其瘢痕旁邻近的正常皮...
详细信息
目的探讨转录因子特异性蛋白1(specificity protein 1,SP1)在NF-κB相关性长链非编码RNA(NF-κB interacting long non-coding RNA,NKILA)影响增生性瘢痕成纤维细胞凋亡中的作用。方法提取并培养增生性瘢痕组织及其瘢痕旁邻近的正常皮肤组织中人皮肤成纤维细胞作为实验细胞系,免疫荧光鉴定成纤维细胞;qRT-PCR检测人瘢痕旁正常皮肤组织来源的成纤维细胞(NSFBs)和增生性瘢痕组织来源的成纤维细胞(HSFBs)中NKILA mRNA的表达水平;构建NKILA的干扰片段,实验分组为:空白对照组、si-NC组、si-NKILA 1组、si-NKILA 2组、si-NKILA 3组,qRT-PCR检测si-NKILA干扰效率;Western blot检测空白对照组、si-NC组、si-NKILA组HSFBs中凋亡指标Bcl-2和Bax的表达水平,流式细胞术检测各组HSFBs凋亡率;构建SP1的干扰片段,实验分组为:空白对照组、si-NC组、si-SP11组、si-SP12组、si-SP13组,qRT-PCR检测si-SP1的干扰效率;qRT-PCR检测干扰转录因子SP1后HSFBs中NKILA mRNA的表达水平。结果与NSFBs相比,NKILA在HSFBs中表达明显升高(P<0.001)。干扰NKILA表达后,Bax蛋白表达水平与Bcl-2蛋白表达水平比值显著增加(P<0.001),HSFBs凋亡率明显增加(P<0.001);干扰转录因子SP1表达后,HSFBs中NKILA的表达下降(P<0.01)。结论lncRNA NKILA抑制增生性瘢痕成纤维细胞凋亡,且受转录因子SP1调控。
暂无评论